Bone loss is associated with aging and is exacerbated by female transition to menopause. Estrogen has long been associated with bone loss, and replacement therapy is effective at restoring bone health. In the last 10 years, pituitary and gonadal peptide hormones have been implicated in bone biology, and here we update the story on FSH and its potential role as a direct regulator of bone and adipose. If translated to humans, new approaches to ameliorate age related bone demise could be developed. Moreover, young women with hormone responsive cancers who are unable to maintain bone may have new routes to avoid debilitating bone loss.
We have been closely following the work of Zaidi and colleagues since their blockbuster paper in Cell, 2006 that said-seemingly out of nowhere-bone loss in women could be explained by high FSH and not loss of estradiol [1] . This immediately caught our attention since young ER+ breast cancer patients who were part of oncofertility programs are at risk, not only for fertility loss, and but also bone loss and cardiovascular disease due to the cancer treatment and the estrogen responsive nature of their disease [2, 3] . The group has once again created news with a Nature, 2017 paper that suggests a similar effect of FSH on adipose [4] . Sophisticated tools including a FSHβ knockout mouse [5] and a new immunoneutralizing FSHβ antibody are the main implements that have been deployed to draw the new compelling data. The authors' first observation was that treatment of male and female mice fed a high-fat diet with the neutralizing FSHβ antibody caused a reduction in fat volume by more than half in both sexes [4] . Fat mass was similarly reduced in ovariectomized mice, and the protective effects of lowering circulating FSH on bone were replicated. Moreover, the mice gained brown adipose tissue and increased thermogenesis. All of these effects and others outlined in the paper lead to the compelling conclusion that FSH is a major hormonal regulator of bone and adipose function in metabolically extreme cases and most likely as part of the normal cyclical management of these organs. Certainly, peri-and postmenopausal changes in weight, cardiovascular function and bone health, are issues that impact women and are particularly acute in women with premature ovarian failure. The finding that FSH may be a culprit is exciting. Unless FSH is somehow acting on the hormonally responsive cancer-which at this point must be explored-having a nonestrogenic way to maintain bone health, in particular, is critically important to breast cancer patients who face enormous lifetime fracture risks. While this is a potential breakthrough, here is what we do not understand:
Neither the bone nor fat effects fit with what we know about effects of FSH suppression using GnRH agonists in humans. Khosla et al. directly examined this question, and limiting FSH levels in postmenopausal women to premenopausal levels had absolutely no effects on bone resorption [6] . Similarly, Finkelstein showing that sex steroid suppression (and FSH suppression) using a GnRH agonist increases fat mass (driven largely by estrogen deficiency, even in men) [7] . Clinically it is known that androgen deprivation therapy using a GnRH agonist in men with prostate cancer causes bone loss and increases fracture risk in men. On the face of it, we have a species difference-a very dissatisfying place to end this discussion. So, what's next?
The caveat to the human data in postmenopausal women is that FSH was reduced from postmenopausal to premenopausal levels with no effect on bone resorption. But what if the real dose response of bone and fat to FSH is below that-i.e., going from premenopausal levels to 0? The studies would have missed that. In the end, the only way to resolve the discordance between all the human data and these mouse findings is to reduce FSH effects to 0 using the FSH antibody. The authors of the mouse study have said that they have identified a human neutralizing epitope and now simply have to humanize an antibody.
It should also be noted that female cancer patients are at higher risk for osteopenia/osteoporosis since they have subfertility and then sterility at an earlier age. Poor bone health remains even when breast cancer patients are on long-term tamoxifen. This is thought to be due to the role of tamoxifen as a partial agonist in the skeleton, but if the FSH-hypothesis is correct, it could be that this weak estrogen is no match for FSH. In the meantime, young ER+ cancer patients are advised to maintain vigorous exercise and supplement with calcium and vitamin D. Routine bone density tests are important to track skeletal health, and bisphosphonates are the next line of therapy if bone loss is documented. A clinical trial of bone health in these at-risk patients would be very welcomed by the field of oncofertility.
As a brief aside, inhibin is another player that must be considered part of this widening endocrine loop [8] . Dana Gaddy showed that inhibin acts on osteoblasts to drive bone deposition, perhaps working as the normal cycle ying to FSHβ's yang operating covertly under an estrogen tone [9] . Finally, while we are on this tangent, we would be remiss if we did not note that activin B is also made by fat, so one could propose that the effects of inhibin may extend to this tissue in order to counteract surge level FSH during normal cycles [10] .
So, we know three things. First, that FSH is not the tissue monogamous hormone we once knew, and at least in mouse, bone and fat are targets. Second, we know that estrogen replacement has profound effects on bone and has been effective in postmenopausal women even in the face of high FSH. And third, we know that if ways other than estrogen exist to manage iatrogenic or age-related bone loss once reproductive function ceases, that would be a good thing to pursue scientifically and clinically.
